TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01701557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: slow fluid rate
Description: 10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fast fluid rate
Description: 20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
Study: NCT02496611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss with pharmacotherapy
Description: Participants randomized to the drug intervention group will receive Exenatide extended-release.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss without pharmacotherapy
Description: Participants randomized to the placebo group will receive a placebo.
Study: NCT02551978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The serious game KOP
Description: The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
Study: NCT02445092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washing the insemination catheter with sperm washing media
Description: Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~* Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~* Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~* Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter.
Study: NCT03798483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised exercise
Description: The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
Study: NCT02289417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01749397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Given IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02036775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-release hard capsule
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-release hard capsule
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-released capsules
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan tablet
Description: One Lasolvan tablet 30 mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-release hard capsule
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-release hard capsule
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan prolonged-release hard capsule
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasolvan effervescent tablet
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Study: NCT03521466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
Study: NCT00835965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 5 mg administered intravenously following endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Study: NCT02094560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP7.1
Description: CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP7.1
Description: CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP7.1
Description: CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
Study: NCT02763449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoing
Description: Participants will self-monitor their physical activity level via activity monitors

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoing
Description: Participants will self-monitor their physical activity level via activity monitors
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.125 mg/kg/h followed by 1 hour at 0.0625 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.75 mg/kg/h followed by 1 hour at 0.375 mg/kg/h
Study: NCT00233324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with target saturation of 91 to 95%
Description: Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with target saturation of 91 to 95%
Description: Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
Study: NCT01749397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given IV
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
Study: NCT00835965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dexamethasone
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
Study: NCT04287335

Intervention type: DIAGNOSTIC_TEST
Intervention: Multitarget stool FIT-DNA test - ColoClear
Description: Multitarget stool FIT-DNA test

Intervention type: DIAGNOSTIC_TEST
Intervention: Multitarget stool FIT-DNA test - ColoClear
Description: Multitarget stool FIT-DNA test

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: fecal immunochemical test

Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: fecal immunochemical test

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: diagnostic colonoscopy
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 2 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 24 hours
Study: NCT04287335

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: diagnostic colonoscopy
Study: NCT03502980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard PowerPICC
Description: PICC Insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard PowerMidline catheter
Description: Midline Insertion
Study: NCT01696851

Intervention type: OTHER
Intervention: tests and questionnaires
Description: lung test, depression and self-efficacy questionnaires and Functional testing.

Intervention type: OTHER
Intervention: tests and questionnaires
Description: lung test, depression and self-efficacy questionnaires and Functional testing.
Study: NCT01366430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gufoni
Description: For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Barbecue
Description: For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
Study: NCT05377892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: High protein followed by reduced protein diet
Study: NCT03805711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT® Transcatheter System
Description: Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
Study: NCT03450174

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In control group, participants will receive only a placebo product

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formative messgaes
Description: In this group, participants will only receive daily formative messages

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified product
Description: In this group, participants will receive fortified product on alternate day up till 8 months

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fortified product plus
Description: In this group participants will receive fortified product on alternate day and formative messages up till 8 months
Study: NCT00626392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
Study: NCT00719420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)
Description: Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin, Amoxicillin, Omeprazole
Description: Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
Study: NCT02010775

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
Study: NCT03832023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening and initiating preventive therapy in communities
Description: Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
Study: NCT00626392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: 325 mg tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: 325 mg tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: 325 mg tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: 325 mg tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin placebo (ASA Pbo)
Description: Tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin placebo (ASA Pbo)
Description: Tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin placebo (ASA Pbo)
Description: Tablets administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin placebo (ASA Pbo)
Description: Tablets administered once daily
Study: NCT00772421

Intervention type: DEVICE
Intervention: There was no intervention.
Description: There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.

Intervention type: DEVICE
Intervention: There was no intervention.
Description: There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
Study: NCT02192320

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg (every evening orally) for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Dexamethasone
Description: Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)
Study: NCT02556229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
Study: NCT00624442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 72 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
Study: NCT01830894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 3 MRI on different times during the study for each arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 3 MRI on different times during the study for each arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 3 MRI on different times during the study for each arm.
Study: NCT03240835

Intervention type: DRUG
Intervention: cisplatin and docetaxel
Description: NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles.

Intervention type: RADIATION
Intervention: IMRT
Description: intensity modulation radiation therapy
Study: NCT03286335

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Radiation treatment
Study: NCT04170751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16 mcg / cc of norepinephrine(group N)
Description: In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4 unit / cc of vasopressin(group V)
Description: In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
Study: NCT04734405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prof-001
Description: Prof-001 cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 150 mg
Description: Fluconazole capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream
Description: ointment base to mimic Prof-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: encapsulated lactose powder to mimic 150 mg fluconazole capsule
Study: NCT00648492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fed